{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:46:49Z","timestamp":1773370009180,"version":"3.50.1"},"posted":{"date-parts":[[2025,10,29]]},"group-title":"Cancer Biology","reference-count":59,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  The BCL2 inhibitor venetoclax has therapeutic activity in several hematological malignancies. In acute myeloid leukemia (AML), venetoclax combined with hypomethylating agents is the standard of care for patients unfit for intensive chemotherapy, but intrinsic and acquired resistance are common. Loss of p53 function is strongly associated with venetoclax resistance, and adding venetoclax to 5-azacitidine provides no overall survival benefit in\n                  <jats:italic>TP53<\/jats:italic>\n                  -mutant AML. Other frequent mechanisms of venetoclax resistance in AML include\n                  <jats:italic>FLT3<\/jats:italic>\n                  mutations, MCL-1 upregulation, and altered mitochondrial metabolism. Unfortunately, it has been challenging to develop agents that target these mechanisms directly and combinatorially. Here we report that pitavastatin, an inhibitor of HMG-CoA-reductase, promotes apoptosis and overcomes several venetoclax resistance mechanisms in human AML cells. At clinically achievable concentrations, pitavastatin treatment has potent cytotoxic activity in cells with mutations in\n                  <jats:italic>TP53<\/jats:italic>\n                  or\n                  <jats:italic>FLT3<\/jats:italic>\n                  . The apoptotic mechanism involves p53-independent PUMA upregulation and reduced MCL-1 expression. Pitavastatin also suppresses mitochondrial gene expression and oxidative metabolism. The pro-apoptotic actions of pitavastatin depend on depletion of geranylgeranyl pyrophosphate (GGPP) and can be recapitulated by inhibiting GGPP synthase or geranylgeranyltransferase-1 enzymes. These results provide a mechanistic rationale for adding pitavastatin to AML regimens to prevent or overcome venetoclax resistance.\n                <\/jats:p>","DOI":"10.1101\/2025.10.27.684888","type":"posted-content","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T23:30:18Z","timestamp":1761780618000},"source":"Crossref","is-referenced-by-count":1,"title":["Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate"],"prefix":"10.64898","author":[{"given":"Roberta","family":"Buono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Juarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhuri","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Skuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishita","family":"Tarnekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhili","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabelle","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A\u2019ishah","family":"Bakayoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Kruidenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said M.","family":"Sebti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela G.","family":"Fleischman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cholsoon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-3735","authenticated-orcid":false,"given":"Martin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-5162","authenticated-orcid":false,"given":"David A.","family":"Fruman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"8","key":"2025110705000480000_2025.10.27.684888v2.1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.trecan.2016.07.001","article-title":"Targeting BCL-2-like Proteins to Kill Cancer Cells","volume":"2","year":"2016","journal-title":"Trends Cancer"},{"key":"2025110705000480000_2025.10.27.684888v2.2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0797"},{"key":"2025110705000480000_2025.10.27.684888v2.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.11.004"},{"key":"2025110705000480000_2025.10.27.684888v2.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"2025110705000480000_2025.10.27.684888v2.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"issue":"6","key":"2025110705000480000_2025.10.27.684888v2.6","first-page":"1","article-title":"Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies","volume":"59","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2025110705000480000_2025.10.27.684888v2.7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0125"},{"key":"2025110705000480000_2025.10.27.684888v2.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003988"},{"issue":"20","key":"2025110705000480000_2025.10.27.684888v2.9","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","year":"2021","journal-title":"Blood"},{"key":"2025110705000480000_2025.10.27.684888v2.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"issue":"24","key":"2025110705000480000_2025.10.27.684888v2.11","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine","volume":"28","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2025110705000480000_2025.10.27.684888v2.12","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","year":"2024","journal-title":"Blood"},{"key":"2025110705000480000_2025.10.27.684888v2.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.010"},{"key":"2025110705000480000_2025.10.27.684888v2.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08137-x"},{"issue":"1","key":"2025110705000480000_2025.10.27.684888v2.15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/bloodadvances.2024014446","article-title":"Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia","volume":"9","year":"2025","journal-title":"Blood Adv"},{"key":"2025110705000480000_2025.10.27.684888v2.16","doi-asserted-by":"crossref","unstructured":"Sharon D , Cathelin S , Mirali S , Di Trani JM , Yanofsky DJ , Keon KA , et al. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019 Oct 30;11(516).","DOI":"10.1126\/scitranslmed.aax2863"},{"key":"2025110705000480000_2025.10.27.684888v2.17","doi-asserted-by":"crossref","unstructured":"Liu F , Kalpage HA , Wang D , Edwards H , H\u00fcttemann M , Ma J , et al. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. Cancers (Basel). 2020 Aug 24;12(9).","DOI":"10.3390\/cancers12092400"},{"issue":"11","key":"2025110705000480000_2025.10.27.684888v2.18","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","year":"2021","journal-title":"Nat Cancer"},{"key":"2025110705000480000_2025.10.27.684888v2.19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0601"},{"key":"2025110705000480000_2025.10.27.684888v2.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.76"},{"issue":"6","key":"2025110705000480000_2025.10.27.684888v2.21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.trecan.2020.11.008","article-title":"Targeting the mevalonate pathway in cancer","volume":"7","year":"2021","journal-title":"Trends Cancer"},{"key":"2025110705000480000_2025.10.27.684888v2.22","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.6"},{"key":"2025110705000480000_2025.10.27.684888v2.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1967"},{"issue":"5","key":"2025110705000480000_2025.10.27.684888v2.24","first-page":"e2078","article-title":"Statins as anti-tumor agents: A paradigm for repurposed drugs","volume":"7","year":"2024","journal-title":"Cancer Rep (Hoboken"},{"key":"2025110705000480000_2025.10.27.684888v2.25","doi-asserted-by":"crossref","unstructured":"Lee JS , Roberts A , Juarez D , Vo T-TT , Bhatt S , Herzog L-O , et al. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 Jun 13;10(445).","DOI":"10.1126\/scitranslmed.aaq1240"},{"issue":"12","key":"2025110705000480000_2025.10.27.684888v2.26","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/2767-9764.CRC-23-0350","article-title":"Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors","volume":"3","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"1","key":"2025110705000480000_2025.10.27.684888v2.27","doi-asserted-by":"crossref","first-page":"22153","DOI":"10.1038\/s41598-020-78315-0","article-title":"Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia","volume":"10","year":"2020","journal-title":"Sci Rep"},{"key":"2025110705000480000_2025.10.27.684888v2.28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.204701"},{"key":"2025110705000480000_2025.10.27.684888v2.29","doi-asserted-by":"crossref","unstructured":"Brem EA , Shieh K , Juarez D , Buono R , Jeyakumar D , O\u2019Brien S , et al. A phase 1 study of adding pitavastatin to venetoclax-based therapy in AML and CLL\/SLL: a tolerable, mechanism-based, drug repurposing strategy. Blood Neoplasia. 2024 Aug;100036.","DOI":"10.1016\/j.bneo.2024.100036"},{"key":"2025110705000480000_2025.10.27.684888v2.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.06.010"},{"key":"2025110705000480000_2025.10.27.684888v2.31","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2015.11"},{"key":"2025110705000480000_2025.10.27.684888v2.32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205534"},{"key":"2025110705000480000_2025.10.27.684888v2.33","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41375-025-02668-6","article-title":"Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response","volume":"39","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"2025110705000480000_2025.10.27.684888v2.34","first-page":"303","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","year":"2017","journal-title":"Leukemia"},{"key":"2025110705000480000_2025.10.27.684888v2.35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0387"},{"key":"2025110705000480000_2025.10.27.684888v2.36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402196"},{"key":"2025110705000480000_2025.10.27.684888v2.37","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0745"},{"key":"2025110705000480000_2025.10.27.684888v2.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.08.070"},{"key":"2025110705000480000_2025.10.27.684888v2.39","doi-asserted-by":"publisher","DOI":"10.1039\/b517572k"},{"key":"2025110705000480000_2025.10.27.684888v2.40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204459"},{"key":"2025110705000480000_2025.10.27.684888v2.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00102-3"},{"key":"2025110705000480000_2025.10.27.684888v2.42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4616"},{"issue":"11","key":"2025110705000480000_2025.10.27.684888v2.43","first-page":"2023","article-title":"Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin","volume":"8","year":"1994","journal-title":"Leukemia"},{"key":"2025110705000480000_2025.10.27.684888v2.44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-044446"},{"key":"2025110705000480000_2025.10.27.684888v2.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.01.021"},{"key":"2025110705000480000_2025.10.27.684888v2.46","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M067488"},{"issue":"19","key":"2025110705000480000_2025.10.27.684888v2.47","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1158\/0008-5472.CAN-24-0970","article-title":"Targeting Cholesterol Biosynthesis with Statins Synergizes with AKT Inhibitors in Triple-Negative Breast Cancer","volume":"84","year":"2024","journal-title":"Cancer Res"},{"issue":"3","key":"2025110705000480000_2025.10.27.684888v2.48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(10)71063-1","article-title":"Pitavastatin - pharmacological profile from early phase studies","volume":"11","year":"2010","journal-title":"Atheroscler Suppl"},{"issue":"3s","key":"2025110705000480000_2025.10.27.684888v2.49","first-page":"3","article-title":"Pitavastatin: a different pharmacological profile","volume":"7","year":"2012","journal-title":"Clin Lipidol"},{"issue":"4","key":"2025110705000480000_2025.10.27.684888v2.50","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2025110705000480000_2025.10.27.684888v2.51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2025110705000480000_2025.10.27.684888v2.52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0028"},{"issue":"4","key":"2025110705000480000_2025.10.27.684888v2.53","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/bloodadvances.2024014633","article-title":"A phase 1 study of the CDK9 inhibitor voruciclib in relapsed\/refractory acute myeloid leukemia and B-cell malignancies","volume":"9","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2025110705000480000_2025.10.27.684888v2.54","doi-asserted-by":"crossref","first-page":"110197","DOI":"10.1016\/j.celrep.2021.110197","article-title":"AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia","volume":"38","year":"2022","journal-title":"Cell Rep"},{"key":"2025110705000480000_2025.10.27.684888v2.55","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18968"},{"issue":"32","key":"2025110705000480000_2025.10.27.684888v2.56","doi-asserted-by":"crossref","first-page":"51435","DOI":"10.18632\/oncotarget.9843","article-title":"Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"2025110705000480000_2025.10.27.684888v2.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0052-4"},{"key":"2025110705000480000_2025.10.27.684888v2.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02103-8"},{"key":"2025110705000480000_2025.10.27.684888v2.59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0130"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.27.684888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:54:56Z","timestamp":1768470896000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.10.27.684888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1101\/2025.10.27.684888","relation":{},"subject":[],"published":{"date-parts":[[2025,10,29]]},"subtype":"preprint"}}